Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Kneat and HCL Technologies Partner to Deliver Digital Validation Solutions to Life Sciences


HALIFAX, Feb. 21, 2019 /CNW/ - kneat.com, inc. (TSXV: KSI) ("Kneat") is pleased to announce that it has signed a partnership agreement with HCL Technologies ("HCL"), a leading global technology company, to provide innovative end-to-end digital validation solutions to customers in the life sciences industry.  HCL has an impressive network and track record within this industry; having decades of experience servicing many of the top bio-pharmaceutical, medical device, contract research, and contract development and manufacturing organizations in the world. 

Logo: kneat.com, inc. (CNW Group/kneat.com, inc.)

This partnership represents a key element in Kneat's strategy to deliver greater value to its current customers and to grow and scale to new customers.  Kneat and HCL will work together on projects to provide and implement next generation digital solutions for facilities, equipment and computer systems validation processes using Kneat's paperless software platform and HCL's experience delivering innovative digital solutions to the life sciences industry.

"This partnership with HCL comes at a pivotal time as the life sciences industry is searching for digital solutions to create efficient and compliant validation processes." said Eddie Ryan, Chief Executive Officer of Kneat.  "We look forward to working with HCL to enhance the value that we deliver to both our customer bases."

"Our partnership with Kneat will further enable us to help our clients disrupt the marketplace with more agile, leaner and standardized validation lifecycle management solutions and services" said Shrikanth Shetty, Executive Vice President ? Head Lifesciences & Healthcare Vertical at HCL Technologies. "We are excited to work with Kneat to further catalyse the digital journey of our clients and enhance overall quality confidence and speed."

About HCL

HCL Technologies (HCL) is a leading global technology company that helps global enterprises reimagine and transform their businesses through Digital technology transformation. The Life Sciences division of HCL Technologies helps clients reimagine their businesses for the digital age through an integrated portfolio of products, solutions and services. Our solutions are built around digital, IoT, cloud, automation, cybersecurity, analytics, infrastructure management, and engineering services, among others. Over decades HCL's validation practice has been partnering with life sciences clients for many leading transformational and run-the-business initiatives. Our 10,000+ Life Sciences Ideapreneurs across 43 countries deliver innovation for over 80% of world's leading life sciences companies in all strategic and functional areas?with a strong focus on R&D, sales and marketing, patient services and supply chain & manufacturing and compliance. For more information, please visit www.hcltech.com or contact [email protected]

About Kneat

Kneat develops and markets the next generation Kneat Gx software platform.  Multiple business processes can be configured on the platform from equipment to computer system validation, through to quality document management.  Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform.  Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide.  Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.  For more information visit www.kneat.com

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes "forward-looking information" within the meaning of applicable Canadian securities laws.  Such forward-looking information, includes, but is not limited to, the relationship between Kneat and HCL, the projects that Kneat and HCL will partner on, Kneat's business development activities, the use of Kneat's software within its customers' manufacturing process, the ability to scale the use of Kneat's software within its customers' organization and the compliance of Kneat's platform under regulatory audit and inspection.  While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties.  As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events.  These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties.  Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws.  Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement.  Continued reliance on forward-looking statements is at an investors' own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE kneat.com, inc.


These press releases may also interest you

at 17:00
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

at 16:45
Geron Corporation , a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...

at 16:33
A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual...



News published on and distributed by: